联用阿托伐他汀与曲美他嗪对冠心病的治疗效果

Therapeutic Effect of Atorvastatin Combined with Trimetazidine on Coronary Heart Disease

目的 分析联用阿托伐他汀与曲美他嗪对冠心病的治疗效果。方法 选取2018年9月至2020年3月我院收治的冠心病患者86例,随机分为对照组与干预组,各43例。对照组仅使用阿托伐他汀治疗,干预组在对照组的基础上增加曲美他嗪,对比两组患者的治疗总有效率和血脂和炎性因子水平、心功能指标、并发症发生情况。结果 干预组患者治疗总有效率为95.35%(41/43),显著高于对照组的79.07%(34/43)(P<0.05)。治疗前,两组的TC、TG、LDL-C、HDL-C水平相比无差异(P>0.05);治疗后,干预组患者的TC、TG、LDL-C指数(2.26±1.22)mmol/L、(1.03±0.55)mmol/L、(1.57±0.05)mmol/L,比对照组的(3.81±1.24)mmol/L、(1.61±0.55)mmol/L、(2.09±0.05)mmol/L低,HDL-C指数为(1.53±0.03)mmol/L,高于对照组(1.01±0.04)mmol/L(P<0.05);干预组患者治疗后Hcy(9.80±3.20)μmol/L、IL-6(17.03±3.20)pg/mL、hs-CRP(7.33±2.50)mg/L均低于对照组(13.40±3.55)μmol/L、(22.39±3.60)pg/mL、(10.48±2.70)mg/L,差异明显(P<0.05);干预组患者LVEF水平(51.01±2.33)%、LVEDD水平(43.23±1.67)%、LVESD(49.37±2.08)%均优于对照组(40.60±1.12)%、(55.23±2.21)%、(59.80±3.66)%,差异有统计学意义(P<0.05);干预组患者心血管不良事件发生率为4.65%(2/43),明显低于对照组20.93%(9/43),差异有统计学意义。结论 在冠心病患者的治疗中,采取阿托伐他汀与曲美他嗪联合使用的方法效果显著,有利于良好改善患者血脂和心功能指标,减少心律失常、心肌梗死、脑卒中等不良心血管疾病的发生风险。

Objective To analyze the therapeutic effect of atorvastatin combined with trimetazidine on coronary heart disease. Methods Eightysix patients with coronary heart disease treated in our hospital from September 2018 to March 2020 were randomly divided into control group and intervention group, with 43 cases in each group. The control group was only treated with atorvastatin, and the intervention group was added with trimetazidine on the basis of the control group. The total effective rate, blood lipid level, cardiac function index and complications of the two groups were compared. Results The total effective rate of the intervention group was 95.35%(41/43), which was significantly higher than 79.07%(34/43) of the control group(P<0.05). Before treatment, there was no difference in the levels of TC, TG, LDL-C and HDL-C between the two groups(P>0.05).After treatment, the indexes of TC, TG and LDL-C in the intervention group were(2.26±1.22) mmol/L,(1.03±0.55) mmol/L and(1.57±0.05) mmol/L, which were lower than those in the control group(3.81±1.24) mmol/L,(1.61±0.55) mmol/L and(2.09±0.05) mmol/L;HDL-C index was(1.53±0.03) mmol/L, which was higher than that in the control group(1.01±0.04) mmol/L(P<0.05). After treatment, Hcy(9.80±3.20) μmol/L, IL-6(17.03±3.20) pg/mL and hs-CRP(7.33±2.50) mg/L in the intervention group were lower than those in the control group(13.40±3.55) μmol/L and(22.39±3.60) pg/mL,(10.48±2.70) mg/L, the difference was significant(P<0.05);the levels of LVEF(51.01±2.33)%, LVEDD(43.23±1.67)%, and LVESD(49.37±2.08)% in the intervention group were significantly higher than those in the control group(40.60±1.12)%,(55.23±2.21)%,(59.80±3.66)%(P<0.05). The incidence of cardiovascular adverse events in the intervention group was as low as 4.65%(2/43), which was significantly lower than 20.93%(9/43) in the control group. Conclusion In the treatment of patients with coronary heart disease, the combination of atorvastatin and trimetazidine is effective, which is conducive to improve the indexes of blood lipid and cardiac function, and reduce the risk of adverse cardiovascular diseases such as arrhythmia, myocardial infarction and stroke.